Cannabis Derivative Cannabidiol Reduces Seizures in Severe …

NEW YORK, May 24, 2017 /PRNewswire-USNewswire/ — After years of anecdotal claims about its benefits, the cannabis derivative cannabidiol reduced seizure frequency by 39 percent for patients with Dravet syndrome – a rare, severe form of epilepsy – in the first large-scale randomized clinical trial for the compound. The findings were published online May 24 in the New England Journal of Medicine.

“Cannabidiol should not be viewed as a panacea for epilepsy, but for patients with especially severe forms who have not responded to numerous medications, these results provide hope that we may soon have another treatment option,” says lead investigator Orrin Devinsky, MD, professor of neurology, neurosurgery, and psychiatry and director of the Comprehensive Epilepsy Center at NYU Langone Medical Center. “We still need more research, but this new trial provides more evidence than we have ever had of cannabidiol’s effectiveness as a medication for treatment-resistant epilepsy.”

Cannabidiol, or CBD, is

... read more at: http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=222550